13F filing recap · Q3 2025
What did Patient Capital Management buy in Q3 2025?
Reported stock-position changes between this filing and the previous one.
Stock value
$2.50B
Positions
41
Estimated turnover
11.8%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Patient Capital Management opened new positions in Strategy Inc and the SPDR S&P 500 ETF Trust, and exited Canada Goose Holdings entirely. UnitedHealth Group, Precigen, Mattel, and Noble Corporation were substantially increased, while Kosmos Energy was substantially reduced. Moderate additions included Energy Transfer, IAC, Biogen, and Crocs, while UBS Group, SoFi Technologies, and Coinbase were moderately trimmed.